Simnotrelvir/Ritonavir

先诺特韦/利托那韦

Report date: 2024/01/22 11:49:35
NME

Base Information

Drug NameSimnotrelvir/Ritonavir
Drug Alias Name先诺欣SIM-0417/RitonavirSSD-8432 / RitonavirSIM-0417 / RitonavirVV934 / Ritonavir
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsSARS-CoV-2-3C-like-proteinase inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatic Insufficiency
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2023/01/28
Country/TerritoryMainland China
CombinationsYes Ritonavir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Simcere Pharmaceutical Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesWuhan Institute Of Virology, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia